CClinicalTrials.gg
RecruitingNCT07853586Updated Oct 6, 2026

Ultrasound-guided Quadratus Lumborum Block Versus Erector Spinae Plane Block for Postoperative Analgesia in Children Undergoing Elective Open Lower Abdominal Surgeries

An interventional study of ultrasound guided anterior oudratus lumborum block and Ultrasound guided erector spinae plane block in Bilateral Inguinal Hernia Repair and Open Upper Abdominal Surgeries, sponsored by Menoufia University. Recruiting at 1 site in Egypt. Open to participants aged 2 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Menoufia University · Not applicable, Interventional, and Supportive care

Updated Oct 2, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
2 Years to 7 Years
Sex
All
01

Study summary

To compare the postoperative analgesic efficacy of ultrasound-guided Quadratus Lumborum Block (anterior approach) versus Erector Spinae Plane Block (T10-T12 level), both performed bilaterally with 0.25% bupivacaine (0.5 mL/kg per side), in the first 24 hours postoperatively in children undergoing elective open lower abdominal surgery under general anesthesia.

02

Conditions studied

  • Bilateral Inguinal Hernia Repair
  • Open Upper Abdominal Surgeries
03

In context

Lead sponsor

Menoufia University is the lead sponsor of 192 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age: 2 to 7 years.
  • ASA Physical Status Classification I or II .
  • Scheduled for elective minor open lower abdominal surgery (bilateral inguinal hernia repair, orchiopexy, circumcision, bilateral hydrocele repair), pyeloplasty and ureteric reimplantation.
  • Weight between 10 and 25 kg.

Exclusion criteria

Exclusion Criteria

  • Known allergy or hypersensitivity to local anesthetics (amide class).
  • Contraindications to regional anesthesia: coagulopathy (INR > 1.5, platelets \< 80,000/mm³), local infection at the injection site, or raised intracranial pressure.
  • Pre-existing neurological, neuromuscular, or spinal disorders.
  • Significant hepatic dysfunction (Child-Pugh Class B or C) or severe renal impairment (eGFR \< 30 mL/min/1.73 m²).
  • Previous abdominal or retroperitoneal surgery which likely to distort fascial planes at the injection site.
  • Emergency or redo surgical procedures.
  • Inability to assess postoperative pain due to pre-existing developmental or cognitive impairment preventing validated pain scale use.
  • Intraoperative conversion from open to laparoscopic approach (post-randomization exclusion criterion).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Ultrasound guided anterior quadratus lumborum block

    Procedure: ultrasound guided anterior oudratus lumborum block

  • Active comparator
    ultrasound guided erector spinae block

    Procedure: Ultrasound guided erector spinae plane block

Interventions

  • Procedureultrasound guided anterior oudratus lumborum block

    A high-frequency linear probe will be used to visualize the structures and a 22G, 80-mm echogenic needle will be inserted to deposit the drug. The probe will be placed above the iliac crest, and Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique, and transversus abdominus muscles) will be identified and will follow posteriorly until the layers of the Thoracolumbar Fascia (TLF) appeared as a bright hyper-echogenic line. The needle will be inserted in-plane along the posterior edge of the probe in anteromedial direction targeting the plane between the quadratus lumborum and psoas major muscle. After confirming the correct needle tip position and negative aspiration for blood, 0.5 mL/kg of 0.25% bupivacaine will be injected incrementally under real-time ultrasound guidance. The procedure will be repeated on the contralateral side.

  • ProcedureUltrasound guided erector spinae plane block

    The patient will be placed in the prone or lateral decubitus position. The ultrasound probe will be positioned para-sagittally approximately 2-3 cm lateral to the midline at the T10-T12 vertebral level. The T11 transverse process will be identified deep to the erector spinae muscle complex. Using an in-plane caudal-to-cranial approach, a 22-gauge echogenic needle will be advanced until the tip contacts the transverse process. Following confirmation of correct plane by injection of 0.5-1 mL saline creating hydrodissection between the erector spinae and transverse process, 0.5 mL/kg of 0.25% bupivacaine will be injected incrementally. The procedure will be repeated contralaterally \].

06

What researchers measure

Primary outcomes

  1. Time of first analgesic request

    Time frame: in the first 24 hours

Secondary outcomes

  1. total opioid (fentanyl equivalent) consumption /ug

    Time frame: the first 24 hours postoperatively

  2. postoperative pain intensity using the FLACC Scale (Face, Legs, Activity, Cry, Consolability) this scale range from 0to10

    Time frame: 0, 30 minutes, 1, 2, 4, 6, 12, and 24 hours postoperatively.

07

Study locations

1 of 1 sites recruiting
  • Menoufia University
    Alexandria, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

2 registry updates since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 2 updates
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: secondary outcomes
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853586
Lead sponsor
Menoufia University
Responsible party
Nevine Mostafa Soliman (Assistant Professor, Menoufia University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Nevine Soliman, MD
Contact
mostafanevine@gmail.com
201128861471

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion